Signal transduction

Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

Retrieved on: 
Tuesday, December 22, 2020
Branches of biology, Biology, Drug discovery, G protein-coupled receptor, Molecular biology, Signal transduction, Small molecule

Targeted protein degradation (TPD) is an approach whereby the body's natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins.

Key Points: 
  • Targeted protein degradation (TPD) is an approach whereby the body's natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins.
  • The collaboration combines Sosei Heptares' structure-based drug design (SBDD) platform, including its structural insights around the target, and its deep understanding of GPCR pharmacology, together with Captor's proprietary TPD Optigrade, platform and extensive know-how and expertise in protein degradation.
  • We are delighted to enter this collaboration with Captor, which has developed multiple novel approaches to identify small molecules that promote TPD.
  • Michal J. Walczak, Chief Scientific Officer of Captor Therapeutics, added:"This is an important partnership for both Captor and Sosei Heptares.

A Genetic Shortcut to Help Visualize Proteins at Work

Retrieved on: 
Thursday, December 10, 2020
Molecular biology, Branches of biology, Biology, Proteomics, Protein, Gladstone Institutes, Signal transduction, Biotechnology

Scientists can visualize these features fairly easily on individual proteins.

Key Points: 
  • Scientists can visualize these features fairly easily on individual proteins.
  • But proteins don't act alone, and scientists also need to know the shape and compositionthe structure, as they call itof the complexes that proteins form when working together.
  • Ultimately, proteins come from genes, and since genes have proven easier to work with than proteins, some scientists are looking to genes and a fast-growing arsenal of genetic tools to facilitate the determination of protein structures.
  • To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impactunsolved diseases.

Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio

Retrieved on: 
Tuesday, December 1, 2020
Branches of biology, Biology, Signal transduction, Calcitonin gene-related peptide receptor antagonists, Calcitonin gene-related peptide, CALCRL, G protein-coupled receptor, Sosei, Receptor antagonist, Receptor

Under the agreement, Biohaven will receive exclusive global rights to develop, manufacture and commercialize a portfolio of novel, small-molecule CGRP receptor antagonists discovered by Sosei Heptares for the treatment of CGRP-mediated disorders.

Key Points: 
  • Under the agreement, Biohaven will receive exclusive global rights to develop, manufacture and commercialize a portfolio of novel, small-molecule CGRP receptor antagonists discovered by Sosei Heptares for the treatment of CGRP-mediated disorders.
  • In addition, Sosei Heptares will be eligible to receive tiered royalties on net sales of products resulting from the collaboration.
  • Vlad Coric, M.D., Chief Executive Officer of Biohaven, said: "We are excited to enter into this agreement with Sosei Heptares, a world leader in GPCR drug discovery.
  • Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, commented:"We are delighted to enter this collaboration and license agreement with Biohaven for our portfolio of novel CGRP receptor antagonists.

RAPT Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Retrieved on: 
Monday, November 23, 2020
Life sciences, Branches of biology, Biology, Chemokine, Cytokines, Signal transduction, Biopharmaceutical, Inflammation, Immunology

A replay of RAPTs fireside chat may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations .

Key Points: 
  • A replay of RAPTs fireside chat may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations .
  • RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.
  • Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases.
  • RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively.

SynDevRx Announces Positive Data from Phase 1 Safety Trial of SDX-7320 in Late Stage Cancer Patients

Retrieved on: 
Monday, November 16, 2020
Drug discovery, Phosphoinositide 3-kinase inhibitor, Clinical medicine, Breast cancer, Cancer, Medicine, Antineoplastic drugs, Signal transduction

Considering the aforementioned data together with this clinical data, we believe SDX-7320 could provide real benefit to breast cancer patients taking a PI3K inhibitor.

Key Points: 
  • Considering the aforementioned data together with this clinical data, we believe SDX-7320 could provide real benefit to breast cancer patients taking a PI3K inhibitor.
  • SynDevRx is pursuing the research and development of therapeutic interventions for cancer patients that also have background metabolic dysfunction.
  • Metabo-oncology is the emerging field of research into, and treatments for cancer patients with tumors that are sensitive to metabolic hormones.
  • SynDevRx intends to initiate a series of clinical studies of its drug candidate SDX-7320 to address this major, unmet medical need.

RAPT Therapeutics to Announce Initial Data from Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications

Retrieved on: 
Sunday, November 15, 2020
Branches of biology, Biology, Life sciences, Cytokines, Chemokine receptors, Cell biology, Chemokine, Signal transduction, Inflammation, CCR4, Biopharmaceutical

RAPT will host a conference call accompanied by a slide presentation at 8:30 a.m.

Key Points: 
  • RAPT will host a conference call accompanied by a slide presentation at 8:30 a.m.
  • The live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations .
  • RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.
  • RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively.

Surrozen to Present at the Stifel 2020 Virtual Healthcare Conference

Retrieved on: 
Thursday, November 12, 2020
Branches of biology, Biology, G protein-coupled receptors, Cell biology, Frizzled, Wnt signaling pathway, LRP5, Retinoic acid-inducible orphan G protein-coupled receptor, Cell signaling, Signal transduction

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that Craig Parker, president and chief executive officer of Surrozen, will be presenting at the Stifel 2020 Virtual Healthcare Conference.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that Craig Parker, president and chief executive officer of Surrozen, will be presenting at the Stifel 2020 Virtual Healthcare Conference.
  • The presentation will begin at 10:40 a.m. Eastern on Monday November 16th, 2020.
  • Modulation of Wnt signaling pathways has potential for treatment of degenerative diseases and tissue injuries.
  • There are 19 Wnt ligands (Wnts) in mammals, and they signal through Frizzled receptors 1-10 and co-receptors LRP5 or 6, two families of receptors.

TaiGen Partners with GPCR to develop Burixafor & Taigexyn(R)

Retrieved on: 
Monday, November 9, 2020
Branches of biology, Biology, G protein-coupled receptors, Biochemistry, Signal transduction, Heteromer

Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn in S. Korea and Burixafor worldwide.

Key Points: 
  • Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn in S. Korea and Burixafor worldwide.
  • Apart from upfront fees, TaiGen will receive shares of GPCR Therapeutics as well as future milestone and royalty payments.
  • CXCR4 antagonism is a well-accepted avenue towards cancer therapy and GPCR Therapeutics is well experienced and possesses the necessary know-how to develop Burixafor in the oncology field.
  • Based in Seoul, S. Korea, GPCR Therapeutics is a biopharmaceutical company developing drugs based on the novel science of GPCR (G Protein-Coupled Receptor) heteromers.

Interim Data From Imago BioSciences’ Phase 2b Study of Bomedemstat (IMG-7289) for Treatment of Myelofibrosis to Be Presented at 62nd American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 5, 2020
Health, Other Science, General Health, Clinical trials, Research, Science, Biotechnology, Blood disorders, Blood, Hematopathology, Branches of biology, Tyrosine kinases, Janus kinase, Signal transduction, Polycythemia vera, Thrombocythemia, Polycythemia, Essential thrombocythemia, Morpholines, Bomedemstat (IMG-7289), Imago BioSciences

An abstract containing preliminary findings will be published in the meeting program on Nov. 5, with updated findings presented during the oral session.

Key Points: 
  • An abstract containing preliminary findings will be published in the meeting program on Nov. 5, with updated findings presented during the oral session.
  • MF patients who are resistant to, intolerant of, or ineligible for a Janus Kinase (JAK) inhibitor are eligible for the study of bomedemstat as monotherapy.
  • In addition to the MF study, bomedemstat is also being evaluated for the treatment of essential thrombocythemia and polycythemia vera.
  • Imago is advancing the clinical development of its first LSD1 inhibitor, bomedemstat, for the treatment of myeloid neoplasms.

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2020 Financial Results - Management to host conference call and webcast on November 12th at 5:00 pm EST / 2:00 pm PST

Retrieved on: 
Thursday, November 5, 2020
Branches of biology, Protein biosynthesis, Biology, aTyr Pharma, Aminoacyl tRNA synthetase, Transfer RNA, Signal transduction

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

Key Points: 
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.
  • aTyrs primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.